Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.39 |
| ▸ | ESR1 | P03372 | 11/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141064 | 0.81 | ESR2 (0.37) | ESR2ESR1MEN1GLAKMT2A | |
| SCHEMBL6141059 | 0.62 | MEN1 (0.51) | SHBGESR2ESR1MEN1GLA | |
| SCHEMBL27944894 | 0.61 | DYRK1A (0.46) | SHBGESR2ESR1MEN1KMT2A | |
| SCHEMBL3649497 | 0.61 | SHBG (0.71) | SHBGESR2ESR1CYP2D6TSHR | |
| SCHEMBL13875399 | 0.61 | SHBG (0.71) | SHBGESR2ESR1CYP2D6TSHR | |
| SCHEMBL15355998 | 0.60 | PDE9A (0.36) | NPC1RAB9A | |
| SCHEMBL3655423 | 0.59 | SHBG (0.57) | SHBGESR2ESR1NFKB1 | |
| SCHEMBL14489029 | 0.59 | SHBG (0.51) | SHBGMEN1KMT2ACYP2D6TSHR | |
| SCHEMBL6063227 | 0.57 | KMT2A (0.31) | ESR2MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL11631602 | 0.57 | CYP19A1 (0.44) | ESR2ESR1MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | claimed |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | MERCK & CO., INC. | 2008-07-03 | — | — | US | claimed |
| EP-1734960-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | claimed |
| WO-2005099704-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | claimed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | claimed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | claimed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | claimed |
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | MERCK & CO., INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1734960-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005099704-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | SHBG 18/4885ESR2 2/4885ESR1 5/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | SHBG 18/4885ESR2 2/4885ESR1 5/4885 |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | EDNRA, GPER1, EDNRB | SHBG 67/4885ESR2 8/4885ESR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.